A Prospective Study in Patients Undergoing Primary Ventral Hernia Repair Using Parietex™ Composite Ventral Patch

Medtronic - MITG126 enrolled

Overview

The objective of this study is to assess the recurrence rate following the use of PARIETEX™ Composite Ventral Patch in primary ventral hernia repair by open approach with intra-peritoneal positioning.

Prospective, multicenter, multinational non-comparative study. Primary Endpoint: Primary hernia recurrence\* rate at 24 month follow-up. The evaluation of hernia recurrence will be performed during a physical examination and by ultrasonography. Secondary Endpoints: Primary hernia recurrence\* rate at 1, 6 and 12 month follow-up. The evaluation of hernia recurrence will be performed during a physical examination and confirmed by ultrasonography. (\*Recurrence is defined as a clinically manifested bulge or a protrusion exacerbated by a Valsalva maneuver.) Safety Parameters: Deep and superficial infection (A Surgical Site Infection (SSI) will be defined in the study according to the Centers for Disease Control and Prevention (CDC) criteria for diagnosis of SSI). Pain / Chronic pain Other post-operative complications (complications related to visceral adhesions, Ileus, seroma, hematoma...) Analgesics consumption Risk factors (severity and treatment) Efficacy Parameters: Recurrence of primary ventral hernia Operative time Time of the mesh positioning Length of Hospital Stay Ease of use (Mesh handling and manipulability, comfort of use …) Return to daily activities/ work Patient satisfaction Patient comfort (Carolina's™ Comfort scale (CCS) - QoL questionnaire) Visit Schedule: Baseline visit (Preoperative) \& Operative/Discharge visit Post-Op: Phone call Day 10 1 month 6 months 12 months 24 months Duration: 12 months recruitment and 24 months follow-up Up to 12 sites in Europe and the United States will be included in this study

Study Type

OBSERVATIONAL

Enrollment

126

Conditions

Hernia

Interventions

PARIETEX™ Composite Ventral PatchDEVICE

PARIETEX™ Composite Ventral Patch for ventral hernia repair

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients (adult ≥ 18 years) at participating centres undergoing primary ventral hernia repair with the device by open approach * Signed informed consent form by the patient or the legally authorized representative * Intraoperative inclusion criteria :Size of the defect: ≤ 4 cm Exclusion Criteria: * Emergency procedure * Current participation in other trials * History of previous hernia at the same location. * Pregnant women: Women who are known or suspected to be pregnant, or who are planning to become pregnant during the study follow-up period * Patient \< 18 years * BMI \> 35 * ASA score ≥ 4 * The investigator determined that the patient will not be able to comply with the required follow-up visits

Locations (10)

University of South Florida

Tampa, Florida, United States

Our Lady of the Lake Regional Medical Center

Baton Rouge, Louisiana, United States

Surgicare of Missouri

Jefferson City, Missouri, United States

Outcomes

Primary Outcomes

Primary Hernia Recurrence Rate at 24 Month Follow-up.

The number of participants with hernia recurrence at 24 months, assessed during a physical examination and by ultrasonography.

Time frame: 24 month follow-up

Secondary Outcomes

Recurrence Rate at 1, 6 and 12 Month Follow-up

The number of participants with hernia recurrence at 1 month, 6 month and 12 month follow-up visit.

Time frame: 1, 6 and 12 month follow-up.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.